Clinical Trials- Pancreatic

 TITLE

 PHASE

 CONTACT

 LOCATION

 A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (RTOG 0848)

 III

 Lisa Pfeifer  lisa.pfeifer@nmhs.org     402-354-8250

Nebraska Methodist Hospital, Omaha, NE

 "A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy
and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic
Adenocarcinoma (ACOSOG Z5041)"

 II

 Natasha Wilson, nwilson@mvcc.cc  402-991-8070 x203

 Missouri Valley Cancer Consortium, Omaha, NE

A Phase I Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients with Locally Advanced Pancreatic Cancer

 I

Deborah Meyer, RN, BGS

 (402) 559-6941

(Email)  dmeyerk@unmc.edu

 or Beth Kos (Ricklefs)

 Nebraska Medical Center, Omaha, NE

A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients with Unresectable or Metastatic Pancreatic and Biliary Tract Cancer

 I

 Deborah Meyer, RN, BGS

 (402) 559-6941

(Email)  dmeyerk@unmc.edu

or Beth Kos (Ricklefs)

 Nebraska Medical Center, Omaha, NE

A Phase III Study of Chemotherapy and Chemoradiotherapy with or without Hyperacute-Pancreas (algenpantucel-L) Immunotherapy in Subjects with Surgically Resected Pancreatic Cancer (NLG0405)

 III

 Deborah Meyer, RN, BGS

 (402) 559-6941

(Email)  dmeyerk@unmc.edu

Beth Kos (Ricklefs)

 Nebraska Medical Center, Omaha, NE

 Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy (SWOG S1115)

 II

 Good Samaritan – Michaela Sherbeck - michaelasherbeck@catholichealth.net

 Good Samaritan Cancer Center, Kearney, NE

 A Phase III trial evaluating Erlotinib (PROVIDED BY STUDY) as adjuvant treatment or Gemcitabine + Erlotinib 2nd randomization includes both arms + radiation and F5U or Capecitabine or Erlotinib and Erlotinib and Gemcitabine  (RTOG 0848)

NCT01013649

III

 JoAnn Wilde 402-717-4714, joann.wilde@alegent.org

 

 

 

CHI

A Randomized, Double-Blind, Phase III Study of the JAK 1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or are Intolerant to First-Line Chemotherapy (The JANUS 1 Study) - INCB 18424-362

III

 Faye Park, fpark@nebraskacancer.com, 402-691-6972

Nebraska Cancer Specialists, Omaha, NE

A Phase I/II , Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in combination with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer

I/II

 Faye Park, fpark@nebraskacancer.com, 402-691-6972

Nebraska Cancer Specialists, Omaha, NE

An International, Multi-center, Open-Label, Randomized, Phase III trial if Y-Clivatuzumab Tetraxetan (Y-hPAM4) plus low dose Gemcitabine and best supportive care versus best supportive care alone in patients with Metastatic (IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments

 

 

 

 

 

 

 

Celgene: ABI-007-PANC-003:  A Phase 3, Multicenter, Open-Label, Randomized Study of nab®-PACLITAXEL Plus Gemcitabine versus

Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

 

 Lisa Pfeifer  lisa.pfeifer@nmhs.org     402-354-8250

Nebraska Methodist Hospital, Omaha, NE

E2211: A Randomized Phase IIStudy of Temozolomide or Temozolomide and

Capecitabine in Patients with Advanced Pancreatic  Neuroendocrine Tumors

 

 

 Lisa Pfeifer  lisa.pfeifer@nmhs.org     402-354-8250

Nebraska Methodist Hospital, Omaha, NE

 

 

 

 

Methodist updated 10/18/14

CHI updated 12/4/14

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508
sarahd@nebmed.org (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software